Literature DB >> 36271295

Impaired muscle strength is associated with ultrastructure damage in myositis.

Andrea Aguilar-Vazquez1,2, Efrain Chavarria-Avila2,3,4, Mario Salazar-Paramo5,6, Juan Armendariz-Borunda7,8, Guillermo Toriz-González9, Marcela Rodríguez-Baeza10, Ana Sandoval-Rodriguez7, Arisbeth Villanueva-Pérez11, Marisol Godínez-Rubí12, Jose-David Medina-Preciado13,14, Ingrid Lundberg15, Yesenia Lozano-Torres2,6, Cynthia-Alejandra Gomez-Rios2, Oscar Pizano-Martinez2,4,14,16, Erika-Aurora Martinez-Garcia2,16, Beatriz-Teresita Martin-Marquez2,16, Sergio Duran-Barragan2,4,16,17, Brenda-Lucia Palacios-Zárate4, Arcelia Llamas-Garcia4, Livier Gómez-Limón4, Monica Vazquez-Del Mercado18,19,20,21.   

Abstract

The muscle fiber ultrastructure in Idiopathic Inflammatory Myopathies (IIM) has been scarcely explored, especially in Inclusion Body Myositis. The aim of this study was to implement the Scanning Electron Microscopy (SEM) in a small cohort of IIM patients, together with the characterization of immunological profile for a better understanding of the pathophysiology. For immunological profile characterization, we identified the presence of autoantibodies (Ro-52, OJ, EJ, PL7, PL12, SRP, Jo-1, PMScl75, PMScl100, Ku, SAE1, NXP2, MDA5, TIF1γ, Mi-2α, Mi-2β) and quantified cytokines (IL-1β, IFN-α2, IFN-γ, TNF-α, IL-6, IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33) and chemokines (CCL2, CXCL8). The histological analysis was made by hematoxylin-eosin staining while the muscle fiber ultrastructure was characterized by SEM. We observed changes in the morphology and structure of the muscle fiber according to muscle strength and muscle enzymes. We were able to find and describe muscle fiber ultrastructure with marked irregularities, porosities, disruption in the linearity and integrity of the fascicle, more evident in patients with increased serum levels of muscle enzymes and diminished muscle strength. Despite the scarce reports about the use of SEM as a tool in all clinical phenotypes of IIM, our work provides an excellent opportunity to discuss and reframe the clinical usefulness of SEM in the diagnostic approach of IIM.
© 2022. The Author(s).

Entities:  

Year:  2022        PMID: 36271295     DOI: 10.1038/s41598-022-22754-4

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.996


  41 in total

1.  Ultrastructural changes in polymyositis.

Authors:  S Matsubara; W G Mair
Journal:  Brain       Date:  1979-12       Impact factor: 13.501

Review 2.  Idiopathic inflammatory myopathies: diagnostic criteria, classification and epidemiological features.

Authors:  Sally Cox; Vidya Limaye; Catherine Hill; Peter Blumbergs; Peter Roberts-Thomson
Journal:  Int J Rheum Dis       Date:  2010-05       Impact factor: 2.454

3.  Immunohistochemical and ultrastructural analysis of sporadic inclusion body myositis: a case series.

Authors:  Katarzyna Haczkiewicz; Agata Sebastian; Aleksandra Piotrowska; Maria Misterska-Skóra; Agnieszka Hałoń; Marta Skoczyńska; Maciej Sebastian; Piotr Wiland; Piotr Dzięgiel; Marzenna Podhorska-Okołów
Journal:  Rheumatol Int       Date:  2018-12-08       Impact factor: 2.631

4.  Histological, SEM and three-dimensional analysis of the midfacial SMAS - New morphological insights.

Authors:  T Sandulescu; H Buechner; D Rauscher; E A Naumova; W-H Arnold
Journal:  Ann Anat       Date:  2018-11-22       Impact factor: 2.698

Review 5.  A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy.

Authors:  Minoru Satoh; Shin Tanaka; Angela Ceribelli; S John Calise; Edward K L Chan
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

Review 6.  Assessment of patients with idiopathic inflammatory myopathies and isolated creatin-kinase elevation.

Authors:  L Iaccarino; E Pegoraro; L Bello; S Bettio; E Borella; L Nalotto; C Semplicini; G Sorarù; A Ghirardello; A Doria
Journal:  Auto Immun Highlights       Date:  2014-10-15

7.  Age- and Severity-Associated Humoral Immunity Response in COVID-19 Patients: A Cohort Study from Wuhan, China.

Authors:  An Zhu; Min Liu; Yang Li; Qing Lei; Qiaoyi Wu; Mingxi Lin; Danyun Lai; Linfang Lu; Siqi Yu; Shujuan Guo; Hewei Jiang; Hongyan Hou; Yunxiao Zheng; Xuening Wang; Mingliang Ma; Bo Zhang; Hong Chen; Junbiao Xue; Hainan Zhang; Huan Qi; Ziyong Sun; Feng Wang; Xionglin Fan; Shengce Tao; Zhaowei Xu
Journal:  J Clin Med       Date:  2022-10-10       Impact factor: 4.964

8.  2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups.

Authors:  Ingrid E Lundberg; Anna Tjärnlund; Matteo Bottai; Victoria P Werth; Clarissa Pilkington; Marianne de Visser; Lars Alfredsson; Anthony A Amato; Richard J Barohn; Matthew H Liang; Jasvinder A Singh; Rohit Aggarwal; Snjolaug Arnardottir; Hector Chinoy; Robert G Cooper; Katalin Dankó; Mazen M Dimachkie; Brian M Feldman; Ignacio Garcia-De La Torre; Patrick Gordon; Taichi Hayashi; James D Katz; Hitoshi Kohsaka; Peter A Lachenbruch; Bianca A Lang; Yuhui Li; Chester V Oddis; Marzena Olesinska; Ann M Reed; Lidia Rutkowska-Sak; Helga Sanner; Albert Selva-O'Callaghan; Yeong-Wook Song; Jiri Vencovsky; Steven R Ytterberg; Frederick W Miller; Lisa G Rider
Journal:  Ann Rheum Dis       Date:  2017-10-27       Impact factor: 19.103

9.  Composition, Architecture, and Functional Implications of the Connective Tissue Network of the Extraocular Muscles.

Authors:  Linda K McLoon; André Vicente; Krysta R Fitzpatrick; Mona Lindström; Fatima Pedrosa Domellöf
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-01-01       Impact factor: 4.799

Review 10.  The Spectrum of Mitochondrial Ultrastructural Defects in Mitochondrial Myopathy.

Authors:  Amy E Vincent; Yi Shiau Ng; Kathryn White; Tracey Davey; Carmen Mannella; Gavin Falkous; Catherine Feeney; Andrew M Schaefer; Robert McFarland; Grainne S Gorman; Robert W Taylor; Doug M Turnbull; Martin Picard
Journal:  Sci Rep       Date:  2016-08-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.